Revive Therapeutics Ltd C.RVV

You guys do realize...

[Trippedstocks]

that was the 400 interim results/update right? "The recently selected dosage". So think about it, we have had 165 test subjects completed. 70 from the 210 and 95 from the next 190 (400 patent total) That's it. EUA on that? Not anytime soon.

50 sites? Wasn't that supposed to be aggressively pursued months ago? It has taken 7 months to get 400 completed. So 600 at end of September at the earliest at this enrollment rate. With vaccinations, and exclusion criteria, we are getting slim on available patients.

[TheTerminator1]

Stop whining!

[Trippedstocks]

it's called accountability! I am also providing a more realistic time line than "I expect multiple news releases" "I expect a halt this week" "this is the big one coming next" Stop trying to be the RVV prophet.

[TheTerminator1]

RVV will become much bigger than you can imagine...It's all coming together

[captainbrouwer]

I agree none of us will know whether bucillamine's effective until the study is unblinded. Anyone who says it's a foregone conclusion is wrong. Appreciated your breakdown Trippedstocks. I'm a bit concerned about enrollment too, but I don't think to the same extent as you. 

[captainbrouwer]

Sotrovimab given EUA for covid recently at 583 patients. 291 received sotrovimab, 292 placebo. Bucillamine trial until now has been 1:1:1 300g:600g:placebo. So 66% have had bucillamine, i.e. 266 patients. Pretty damn close to 291. Only half of them had the 600g dose they've selected to continue for rest of study, but that 300g data is surely still valuable. The question is how valuable. I don

[90guppy]

Right on! and watch out for licensing deals before that, that could be massive catalyst too, while waiting for EUA Example of big licensing deals

[TheTerminator1]

I like your post,it's more than realistic!

[Trippedstocks]

the 1:1:1 ended after the 210 first interim analysis in February. 600mg dosage was selected then. You are correct on the 2:1. My math is off. So 70 took 600mg then 126 from the next 190 patients. So 196 have the 600mg and 70 have the 300mg. I do know the study can end early and EUA approval prior to 1000 patients. It will still be end of September even October. We can only assume Bucillamine is

[captainbrouwer]

Ah, my mistake. Well, that's even better since it means more patients have had the selected 600mg dose